Drawing for CAP-T

USPTO serial 79084150

CAP-T

Reviewed by CopyMark Law Group

Reg. 4036922Status 404
Filing date
Status date
Registration date
Oct 11, 2011
Examiner
POVARCHUK, REBECCA JOYCE
Law office
MADRID PROCESSING UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CAP-T?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey H. Kamenetsky

JEFFREY H. KAMENETSKY CHRISTOPHER & WEISBERG, P.A.200 EAST LAS OLAS BOULEVARDSUITE 2040FORT LAUDERDALE, FL 33301

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of chemicals, biologicals and biochemicals, namely, preparations and reagents for non medical use, in particular for scientific, research, laboratory, industrial and commercial purposes; chemical, biological and biochemical additives, preparations and reagents for research and characterisation of diseases for non-medical purposes; chemical, biological and biochemical additives, preparations and reagents, namely, cell lines, cells, proteins and polypeptides, for scientific and medical research and development of pharmaceuticals; chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of medicines and pharmaceuticals; cultures of microorganisms other than for medical and veterinary use; cell lines, cells and amino acids for laboratory or research use; nucleic acid sequences, proteins and polypaptides for other than medical and veterinary use; diagnostic reagents and preparations comprising proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for scientific, research, laboratory, and commercial purposes for the development of medicines and for use in the manufacture of medicines and pharmaceuticalsSECTION 71 - CANCELLED—
005Medicines, chemical, biological and biochemical preparations and proteins for the treatment of cancer, tumourous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardiovascular diseases, except thyreostatica and cough and cold medicines; pharmaceutical and veterinary preparations and reagents for use in the treatment of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatica and cough and cold medicines; chemical, biological and biochemical reagents for medical and veterinary purposes, except thyreostatica and cough and cold medicines; diagnostic and analytic preparations for medical and veterinary purposes; cell lines, cells, diagnostic proteins and polypeptides for medical or clinical use; nucleic acid sequences, diagnostic proteins, polypeptides and chemical reagents for medical and veterinary purposes; amino acids for medical or veterinary purposes; diagnostic reagents and preparations, namely, microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for medical, veterinary and diagnostic purposes, except thyreostatica and cough and cold medicinesSECTION 71 - CANCELLED—
042Scientific and industrial research, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; research and development of medicines, diagnostic and analytic preparations, methods of therapy and expression systems; scientific and technological consulting services, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; industrial consulting services, namely, consultancy pertaining to pharmacology; breeding, recovery, optimisation, synthesis and modification of cell culture lines, cells, microorganisms, polypeptides, proteins, nucleotides, nucleic acids for scientific, research, laboratory, industrial and commercial purposes, namely, for use in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics, for the development of medicines and for use in the manufacture of medicines and pharmaceuticalsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 29, 2021DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
May 29, 2021DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 15, 2019INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jan 28, 2019INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jan 28, 2019INPCINVALIDATION PROCESSED—
Jan 18, 2019INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 18, 2018C71TCANCELLED SECTION 71—
Jun 11, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 21, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 21, 2012FIMPFINAL DISPOSITION PROCESSED—
Jan 11, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 7, 2011LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Oct 29, 2011LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Oct 11, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 26, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 26, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 20, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 16, 2011ALIEASSIGNED TO LIE—
Jun 9, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 9, 2011XAECEXAMINER'S AMENDMENT ENTERED—
Jun 9, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 9, 2011GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 9, 2011CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 7, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 6, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 6, 2011ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Feb 18, 2011GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 18, 2011GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 18, 2011CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 7, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 7, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 7, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 21, 2011ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 21, 2011REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 5, 2010CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Sep 25, 2010RFNTREFUSAL PROCESSED BY IB—
Sep 24, 2010CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Aug 30, 2010RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 30, 2010RFRRREFUSAL PROCESSED BY MPU—
Aug 27, 2010RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 26, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 25, 2010CREVCORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED—
Aug 24, 2010DOCKASSIGNED TO EXAMINER—
Aug 19, 2010CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Aug 19, 2010CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Jul 27, 2010MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 23, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 22, 2010REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance